ICB benefit in breast cancer was first demonstrated in the IMpassion130 trial, where adding atezolizumab (anti-PD-L1) to standard-of-care nab-paclitaxel increased progression-free survival in TNBC patients with ≥1% PD-L1+ immune cells in the tumor [5]. Here, CD274 is linked to breast carcinoma.